PE20081161A1 - COMPUESTOS DE TETRAHIDROCICLOPENTA[b]INDOL COMO MODULADORES DEL RECEPTOR DE ANDROGENOS - Google Patents

COMPUESTOS DE TETRAHIDROCICLOPENTA[b]INDOL COMO MODULADORES DEL RECEPTOR DE ANDROGENOS

Info

Publication number
PE20081161A1
PE20081161A1 PE2007001544A PE2007001544A PE20081161A1 PE 20081161 A1 PE20081161 A1 PE 20081161A1 PE 2007001544 A PE2007001544 A PE 2007001544A PE 2007001544 A PE2007001544 A PE 2007001544A PE 20081161 A1 PE20081161 A1 PE 20081161A1
Authority
PE
Peru
Prior art keywords
tetrahydrocyclopenta
cyane
indol
androgen receptor
receptor modulators
Prior art date
Application number
PE2007001544A
Other languages
English (en)
Spanish (es)
Inventor
Konstantinos Gavardinas
Jonathan Edward Green
Donald Paul Matthews
Prabhakar Kondaji Jadhav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20081161A1 publication Critical patent/PE20081161A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/70[b]- or [c]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
PE2007001544A 2006-11-20 2007-11-08 COMPUESTOS DE TETRAHIDROCICLOPENTA[b]INDOL COMO MODULADORES DEL RECEPTOR DE ANDROGENOS PE20081161A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86648406P 2006-11-20 2006-11-20

Publications (1)

Publication Number Publication Date
PE20081161A1 true PE20081161A1 (es) 2008-08-15

Family

ID=39415431

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001544A PE20081161A1 (es) 2006-11-20 2007-11-08 COMPUESTOS DE TETRAHIDROCICLOPENTA[b]INDOL COMO MODULADORES DEL RECEPTOR DE ANDROGENOS

Country Status (36)

Country Link
US (1) US7968587B2 (enExample)
EP (1) EP2094658B1 (enExample)
JP (1) JP5399259B2 (enExample)
KR (1) KR101121471B1 (enExample)
CN (1) CN101541749B (enExample)
AR (1) AR063559A1 (enExample)
AT (1) ATE538091T1 (enExample)
AU (1) AU2007324046B2 (enExample)
BR (1) BRPI0719092B8 (enExample)
CA (1) CA2670340C (enExample)
CL (1) CL2007003182A1 (enExample)
CO (1) CO6190513A2 (enExample)
CR (1) CR10802A (enExample)
CY (1) CY1112284T1 (enExample)
DK (1) DK2094658T3 (enExample)
EA (1) EA015627B1 (enExample)
EC (1) ECSP099350A (enExample)
ES (1) ES2376048T3 (enExample)
HR (1) HRP20120032T1 (enExample)
IL (1) IL198410A (enExample)
JO (1) JO2800B1 (enExample)
MA (1) MA31072B1 (enExample)
MX (1) MX2009005251A (enExample)
MY (1) MY154547A (enExample)
NO (1) NO342531B1 (enExample)
NZ (1) NZ576296A (enExample)
PE (1) PE20081161A1 (enExample)
PL (1) PL2094658T3 (enExample)
PT (1) PT2094658E (enExample)
RS (1) RS52191B (enExample)
SI (1) SI2094658T1 (enExample)
TN (1) TN2009000189A1 (enExample)
TW (1) TWI398438B (enExample)
UA (1) UA98777C2 (enExample)
WO (1) WO2008063867A2 (enExample)
ZA (1) ZA200903096B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
US8067448B2 (en) 2008-02-22 2011-11-29 Radius Health, Inc. Selective androgen receptor modulators
WO2009140448A1 (en) * 2008-05-16 2009-11-19 Eli Lilly And Company Tetrahydrocyclopenta[b]indole androgen receptor modulators
AR078862A1 (es) 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
MX338831B (es) 2010-02-04 2016-05-03 Radius Health Inc Moduladores selectivos de receptores de androgenos.
SI2568806T1 (sl) 2010-05-12 2016-09-30 Radius Health, Inc. Režimi zdravljenja
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
WO2012152741A1 (de) 2011-05-10 2012-11-15 Bayer Intellectual Property Gmbh Bicyclische (thio)carbonylamidine
CN103265479B (zh) * 2013-06-14 2017-12-08 南开大学 一种6‑氯甲基烟酸叔丁酯的合成方法
PT3122426T (pt) 2014-03-28 2023-02-28 Univ Duke Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
HRP20220619T1 (hr) 2016-06-22 2023-02-03 Ellipses Pharma Ltd Postupci za liječenje ar+ raka dojke
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
ES2981967T3 (es) 2017-01-05 2024-10-14 Radius Pharmaceuticals Inc Formas polimórficas de RAD1901-2HCl
JP7473486B2 (ja) 2018-07-04 2024-04-23 ラジウス ファーマシューティカルズ,インコーポレイテッド Rad1901-2hclの多形形態
JOP20210218A1 (ar) 2019-02-12 2023-01-30 Radius Pharmaceuticals Inc عمليات ومركبات
JP2023511612A (ja) * 2020-01-27 2023-03-20 エイルゲン ファーマ リミテッド 腎臓疾患の治療のためのテトラヒドロシクロペンタ[b]インドール化合物
US11986461B1 (en) * 2023-08-24 2024-05-21 King Faisal University 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
KR100826485B1 (ko) * 1999-10-14 2008-05-02 가켄 세야쿠 가부시키가이샤 테트라히드로퀴놀린 유도체
JP2005527464A (ja) 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー sPLA2インヒビターとしてのシクロヘプタBインドール誘導体
DE10164564B4 (de) 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
WO2003097598A1 (en) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
CN1926104A (zh) * 2004-03-03 2007-03-07 伊莱利利公司 作为类固醇激素核受体调节剂的双环取代的吲哚衍生物
WO2006121466A2 (en) * 2004-11-22 2006-11-16 Smithkline Beecham Corporation Hcv inhibitors
CA2588607A1 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
EP1856126A2 (en) 2005-02-17 2007-11-21 Wyeth a Corporation of the State of Delaware Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
BRPI0611705A2 (pt) 2005-06-24 2016-11-16 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto
WO2007047604A2 (en) 2005-10-18 2007-04-26 Elixir Pharmaceuticals, Inc. Sirt1 inhibition
WO2008019825A1 (en) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
WO2009140448A1 (en) 2008-05-16 2009-11-19 Eli Lilly And Company Tetrahydrocyclopenta[b]indole androgen receptor modulators

Also Published As

Publication number Publication date
CN101541749B (zh) 2013-03-27
CA2670340A1 (en) 2008-05-29
US7968587B2 (en) 2011-06-28
HRP20120032T1 (hr) 2012-02-29
CO6190513A2 (es) 2010-08-19
NO342531B1 (no) 2018-06-11
JO2800B1 (en) 2014-03-15
BRPI0719092A2 (pt) 2013-12-03
AU2007324046A1 (en) 2008-05-29
PT2094658E (pt) 2012-02-22
CY1112284T1 (el) 2015-12-09
UA98777C2 (en) 2012-06-25
IL198410A (en) 2013-09-30
MX2009005251A (es) 2009-08-19
HK1134089A1 (en) 2010-04-16
BRPI0719092B8 (pt) 2021-05-25
RS52191B (sr) 2012-10-31
CN101541749A (zh) 2009-09-23
KR20090082229A (ko) 2009-07-29
CA2670340C (en) 2014-05-20
ZA200903096B (en) 2010-07-28
NO20092103L (no) 2009-05-28
ECSP099350A (es) 2009-06-30
JP2010510231A (ja) 2010-04-02
ATE538091T1 (de) 2012-01-15
NZ576296A (en) 2011-11-25
AR063559A1 (es) 2009-02-04
ES2376048T3 (es) 2012-03-08
JP5399259B2 (ja) 2014-01-29
IL198410A0 (en) 2010-02-17
TWI398438B (zh) 2013-06-11
WO2008063867A3 (en) 2008-07-31
WO2008063867A2 (en) 2008-05-29
SI2094658T1 (sl) 2012-04-30
PL2094658T3 (pl) 2012-05-31
MY154547A (en) 2015-06-30
DK2094658T3 (da) 2012-02-13
CL2007003182A1 (es) 2008-06-27
AU2007324046B2 (en) 2012-04-05
EA200970500A1 (ru) 2009-10-30
EP2094658A2 (en) 2009-09-02
US20100069404A1 (en) 2010-03-18
BRPI0719092B1 (pt) 2020-08-18
MA31072B1 (fr) 2010-01-04
TN2009000189A1 (en) 2010-10-18
CR10802A (es) 2009-07-13
EP2094658B1 (en) 2011-12-21
EA015627B1 (ru) 2011-10-31
KR101121471B1 (ko) 2012-02-28
TW200827347A (en) 2008-07-01

Similar Documents

Publication Publication Date Title
PE20081161A1 (es) COMPUESTOS DE TETRAHIDROCICLOPENTA[b]INDOL COMO MODULADORES DEL RECEPTOR DE ANDROGENOS
PE20121010A1 (es) Derivados de bencimidazol
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
PE20110152A1 (es) Nuevos derivados de sulfamida sustituida
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
PE20142216A1 (es) Inhibidores de indazol de la ruta de senalizacion de wnt y usos terapeuticos de los mismos
PE20060334A1 (es) Derivados de piridina como antagonistas del receptor a2b de adenosina
PE20060737A1 (es) 3-AMINO-PIRAZOL[3,4b] PIRIDINAS COMO INHIBIDORES DE PROTEINTIROSINQUINASAS Y SU PREPARACION
PE20130402A1 (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20091219A1 (es) Inhibidores de 11-beta hidroxiesteroide deshidrogenasa tipo i de triazolopiridina
PE20060949A1 (es) Derivados fusionados de pirazol como agonistas del receptor de niacina
PE20120062A1 (es) Derivados de 1-bencil-2-amino-tetralina como inhibidores del transportador de glicina glyt1
PE20080006A1 (es) Derivados de quinolina como agentes pesticidas
PH12012501456A1 (en) Novel 3-hydroxy -5- arylisothiazole derivative
UY30874A1 (es) Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapéutica.
PE20141678A1 (es) Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
PE20080947A1 (es) Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas como antagonistas de receptores de tipo trpv1
PE20081831A1 (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
PE20070706A1 (es) Nuevos derivados imidazopiridina como antagonistas de adenosina a2b
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
PE20080176A1 (es) Compuestos de arilpiperazina sulfonamida como agonista de los receptores de secretagogos de la hormona de crecimiento (ghs)
PE20061333A1 (es) Derivados de ciclopentapiridina y tetrahidroquinolina como ligandos del receptor 5-ht
AR076841A1 (es) Derivados de triazol-sustituidos, procesos para su preparacion y metodos de uso en el control de plagas

Legal Events

Date Code Title Description
FG Grant, registration